公开(公告)号：US20230165833A1

公开(公告)日：2023-06-01

申请号：US16967401

申请日：2019-09-16

申请人： CHINA PHARMACEUTICAL UNIVERSITY

发明人： Haopeng SUN ,  Hongyu YANG ,  Tingkai CHEN ,  Yao CHEN ,  Feng FENG ,  Chenxi DU

IPC分类号： A61K31/381 ,  A61K31/40 ,  A61K31/341 ,  A61K31/4402 ,  A61K31/426 ,  A61K31/4164 ,  A61K31/167 ,  A61K31/24 ,  A61K31/277 ,  A61P25/28 ,  A61K31/195

CPC分类号： A61K31/381 ,  A61K31/24 ,  A61K31/40 ,  A61K31/167 ,  A61K31/195 ,  A61K31/277 ,  A61K31/341 ,  A61K31/426 ,  A61K31/4164 ,  A61K31/4402 ,  A61P25/28

摘要： The present invention discloses a selective butyrylcholinesterase inhibitor having a general formula (I) or a pharmaceutically acceptable salt thereof, a preparation method and use thereof. The treatment efficacy of Alzheimer’s disease, especially moderate to severe Alzheimer’s disease, is tested through butyrylcholinesterase inhibitory activity, selectivity screening and toxicity to nerve cells as a carrier, and it is found that it has good target activity in vitro, extremely high selectivity and drug safety, can be used as a lead substance for further development of the treatment of Alzheimer’s disease by selectively inhibiting butyrylcholinesterase.